Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.54 |
| ▸ | DRD3 | P35462 | 12/20 | 0.54 |
| ▸ | DRD4 | P21917 | 10/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30042123 | 1.00 | DRD2 (0.54) | DRD2DRD3DRD4ACHEHRH4 | |
| SCHEMBL23964237 | 0.90 | DRD2 (0.54) | DRD2DRD3DRD4ACHEHRH4 | |
| SCHEMBL30041336 | 0.85 | DRD4 (0.55) | DRD2DRD3DRD4ACHEHRH4 | |
| SCHEMBL23932491 | 0.85 | DRD4 (0.55) | DRD2DRD3DRD4ACHEHRH4 | |
| SCHEMBL23964189 | 0.84 | DRD4 (0.51) | DRD2DRD3DRD4HRH4HTR1A | |
| SCHEMBL30041451 | 0.84 | HRH4 (0.63) | DRD2DRD3DRD4HRH4HTR1A | |
| SCHEMBL23964200 | 0.84 | HRH4 (0.63) | DRD2DRD3DRD4HRH4HTR1A | |
| SCHEMBL23964311 | 0.82 | DRD2 (0.51) | DRD2DRD3DRD4HRH4TSHR | |
| SCHEMBL23964281 | 0.82 | SLC2A1 (0.56) | DRD2DRD3DRD4HTR1AADRA2A | |
| SCHEMBL30042026 | 0.82 | DRD2 (0.51) | DRD2DRD3DRD4HRH4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115427404-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021216665-A9 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | DRD2 4780/4885DRD3 4747/4885DRD4 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.